Takahiro Inoue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takahiro Inoue has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Hideki Iijima
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan
28 shared publications Masahiko Tsujii
28 shared publications- Shinichiro Shinzaki
Department of Gastroenterology, Hyogo Medical University School of Medicine, Nishinomiya, Japan
28 shared publications - Tetsuo Takehara
Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan
23 shared publications Satoshi Hiyama
20 shared publications- Tsutomu Nishida
Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan
19 shared publications
Latest Publications
- Open Access
- 30 May 2025
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (3)
Optimizing 5-Aminosalicylic Acid Maintenance Treatment in Ulcerative Colitis from the Patient and Physician Perspective: A Cross-sectional Multicenter Study
Background: There are currently no standardized guidelines for optimizing 5-aminosalicylic acid (5-ASA) maintenance treatment, particularly in patients with ulcerative colitis (UC) who have achieved clinical remission (CR). Therefore, this study examined the perspectives of patients and physicians regarding 5-ASA dose reduction and medication adherence to optimize maintenance treatment. Methods: This cross-sectional study was conducted from February 2023 to May 2023 at 19 institutions and included patients with UC and physicians. The participants’ perspectives were assessed using an anonymous questionnaire. Results: This study included 369 patients with UC (female, 43.1%; age, > 60 years, 29.3%; CR, 88.9%). Preference to reduce the 5-ASA dose and low medication adherence were observed in 46.1% and 16.0% of patients, respectively. Low medication adherence (odds ratio [OR]: 3.43, 95% confidence interval [CI]: 1.67–7.03) was associated with the preference to reduce the 5-ASA dose. Multivariate analysis for factors associated with low medication adherence revealed age < 60 years (OR: 10.25, 95% CI: 3.58–29.38), no intractable disease subsidy (OR: 2.63, 95% CI: 1.09–6.35), dosing frequency ≥ 2 times/day (OR: 9.04, 95% CI: 3.67–22.25), and preference to reduce the 5-ASA dose (OR: 2.57, 95% CI: 1.16–5.70) as significant. Among 153 physicians, 62.7% had > 10 years of experience, and 51.0% regularly verified adherence, with experience being a significant factor (OR: 2.01, 95% CI: 1.10–3.68). Conclusions: Factors influencing medication adherence with 5-ASA included patients’ desire for dose reduction and physicians’ lack of experience. Improving communication with patients and enhancing education for physicians could help optimize treatment with 5-ASA.
- 30 May 2025
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (3)
Open AccessOptimizing 5-Aminosalicylic Acid Maintenance Treatment in Ulcerative Colitis from the Patient and Physician Perspective: A Cross-sectional Multicenter Study
Background: There are currently no standardized guidelines for optimizing 5-aminosalicylic acid (5-ASA) maintenance treatment, particularly in patients with ulcerative colitis (UC) who have achieved clinical remission (CR). Therefore, this study examined the perspectives of patients and physicians regarding 5-ASA dose reduction and medication adherence to optimize maintenance treatment. Methods: This cross-sectional study was conducted from February 2023 to May 2023 at 19 institutions and included patients with UC and physicians. The participants’ perspectives were assessed using an anonymous questionnaire. Results: This study included 369 patients with UC (female, 43.1%; age, > 60 years, 29.3%; CR, 88.9%). Preference to reduce the 5-ASA dose and low medication adherence were observed in 46.1% and 16.0% of patients, respectively. Low medication adherence (odds ratio [OR]: 3.43, 95% confidence interval [CI]: 1.67–7.03) was associated with the preference to reduce the 5-ASA dose. Multivariate analysis for factors associated with low medication adherence revealed age < 60 years (OR: 10.25, 95% CI: 3.58–29.38), no intractable disease subsidy (OR: 2.63, 95% CI: 1.09–6.35), dosing frequency ≥ 2 times/day (OR: 9.04, 95% CI: 3.67–22.25), and preference to reduce the 5-ASA dose (OR: 2.57, 95% CI: 1.16–5.70) as significant. Among 153 physicians, 62.7% had > 10 years of experience, and 51.0% regularly verified adherence, with experience being a significant factor (OR: 2.01, 95% CI: 1.10–3.68). Conclusions: Factors influencing medication adherence with 5-ASA included patients’ desire for dose reduction and physicians’ lack of experience. Improving communication with patients and enhancing education for physicians could help optimize treatment with 5-ASA.
- 1 October 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 60 (10) , 439-444
Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient
A 60-year-old man was treated with a regimen of controlled-release tacrolimus (2 mg once daily), everolimus (0.5 mg twice daily), methylprednisolone (4 mg once daily), and mizoribine (100 mg twice daily) as an anti-rejection regimen following living-donor kidney transplantation. One year after transplantation, the recipient was admitted to Mie University Hospital (day X; admission date) to treat coronavirus disease 2019 pneumonia. The latest trough concentrations of tacrolimus and everolimus before admission (day X-65) were 4.5 ng/mL and 4.4 ng/mL, respectively. Since tacrolimus concentration was 4.2 ng/mL on day X+3, the dose was adjusted to 1.5 mg once daily to reach the target concentration of 3.0 ng/mL due to the introduction of remdesivir. After starting remdesivir on day X+4, the increased trough concentrations of tacrolimus on day X+6 (6.9 ng/mL) and everolimus on day X+7 (9.2 ng/mL) were observed, which resulted in dose reduction of tacrolimus (0.5 mg once daily) and discontinuation of everolimus. After discontinuation of remdesivir on day X+9, dose titration of controlled-release tacrolimus and restart of everolimus (0.5 mg twice daily) were performed from day X+15. The dose of controlled-release tacrolimus was titrated and fixed to 2 mg once daily at discharge (day X+21). There was no toxicity due to immunosuppressive agents during hospitalization. This case report indicated that remdesivir might interact with cytochrome P450 3A4 substrates, such as tacrolimus and everolimus, and elevate their blood concentrations under high inflammatory conditions.
- 1 October 2022
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 60 (10) , 439-444
Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient
A 60-year-old man was treated with a regimen of controlled-release tacrolimus (2 mg once daily), everolimus (0.5 mg twice daily), methylprednisolone (4 mg once daily), and mizoribine (100 mg twice daily) as an anti-rejection regimen following living-donor kidney transplantation. One year after transplantation, the recipient was admitted to Mie University Hospital (day X; admission date) to treat coronavirus disease 2019 pneumonia. The latest trough concentrations of tacrolimus and everolimus before admission (day X-65) were 4.5 ng/mL and 4.4 ng/mL, respectively. Since tacrolimus concentration was 4.2 ng/mL on day X+3, the dose was adjusted to 1.5 mg once daily to reach the target concentration of 3.0 ng/mL due to the introduction of remdesivir. After starting remdesivir on day X+4, the increased trough concentrations of tacrolimus on day X+6 (6.9 ng/mL) and everolimus on day X+7 (9.2 ng/mL) were observed, which resulted in dose reduction of tacrolimus (0.5 mg once daily) and discontinuation of everolimus. After discontinuation of remdesivir on day X+9, dose titration of controlled-release tacrolimus and restart of everolimus (0.5 mg twice daily) were performed from day X+15. The dose of controlled-release tacrolimus was titrated and fixed to 2 mg once daily at discharge (day X+21). There was no toxicity due to immunosuppressive agents during hospitalization. This case report indicated that remdesivir might interact with cytochrome P450 3A4 substrates, such as tacrolimus and everolimus, and elevate their blood concentrations under high inflammatory conditions.
- Open Access
- 28 April 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (8) , 1561-1570
Exacerbation of non‐steroidal anti‐inflammatory drug‐induced enteropathy in C‐C chemokine receptor type 7‐deficient mice
Background and Aim: Non‐steroidal anti‐inflammatory drugs (NSAIDs) induce intestinal enteropathy and the pathophysiology is related to immune‐mediated mechanisms. We aimed to investigate the role of C‐C chemokine receptor type 7 (CCR7) which regulates immune cell migration in NSAID‐induced enteropathy.Methods: Injury of the small intestine was evaluated 24 h after the subcutaneous injection of indomethacin in CCR7‐deficient (Ccr7−/−) and wild‐type (WT) mice. The cellular profile and cytokine production in intestinal cells were analyzed. Indomethacin‐induced enteropathy was evaluated in mice adoptively transferred with CD103+ dendritic cells (DCs) from Ccr7−/− or WT mice.Results: Indomethacin induced more severe intestinal injury in Ccr7−/− mice than in WT mice. The major inflammatory cytokines were not increased and the proportion of regulatory T cells following indomethacin injection was not decreased in Ccr7−/− mice compared with WT mice. The expression of interleukin (IL)‐22 binding protein (IL‐22BP), which inhibits IL‐22 activity, was significantly higher in CD103+ DCs from Ccr7−/− mice than those from WT mice. Mice adoptively transferred with CD103+ DCs isolated from Ccr7−/− mice exhibited more severe intestinal injury following indomethacin injection compared with those adoptively transferred with CD103+ DCs of WT mice. Ccr7−/− mice injected with indomethacin showed a significant reduction in regenerating islet‐derived 1 (Reg1) mRNA expression, which is regulated by IL‐22, in intestinal epithelial cells.Conclusions: C‐C chemokine receptor type 7 deficiency exacerbated NSAID‐induced enteropathy in association with an altered phenotype of CD103+ DCs that produces IL‐22BP. CCR7 contributes to protect the small intestine from NSAID‐induced mucosal injury.
- 28 April 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (8) , 1561-1570
Open AccessExacerbation of non‐steroidal anti‐inflammatory drug‐induced enteropathy in C‐C chemokine receptor type 7‐deficient mice
Background and Aim: Non‐steroidal anti‐inflammatory drugs (NSAIDs) induce intestinal enteropathy and the pathophysiology is related to immune‐mediated mechanisms. We aimed to investigate the role of C‐C chemokine receptor type 7 (CCR7) which regulates immune cell migration in NSAID‐induced enteropathy.Methods: Injury of the small intestine was evaluated 24 h after the subcutaneous injection of indomethacin in CCR7‐deficient (Ccr7−/−) and wild‐type (WT) mice. The cellular profile and cytokine production in intestinal cells were analyzed. Indomethacin‐induced enteropathy was evaluated in mice adoptively transferred with CD103+ dendritic cells (DCs) from Ccr7−/− or WT mice.Results: Indomethacin induced more severe intestinal injury in Ccr7−/− mice than in WT mice. The major inflammatory cytokines were not increased and the proportion of regulatory T cells following indomethacin injection was not decreased in Ccr7−/− mice compared with WT mice. The expression of interleukin (IL)‐22 binding protein (IL‐22BP), which inhibits IL‐22 activity, was significantly higher in CD103+ DCs from Ccr7−/− mice than those from WT mice. Mice adoptively transferred with CD103+ DCs isolated from Ccr7−/− mice exhibited more severe intestinal injury following indomethacin injection compared with those adoptively transferred with CD103+ DCs of WT mice. Ccr7−/− mice injected with indomethacin showed a significant reduction in regenerating islet‐derived 1 (Reg1) mRNA expression, which is regulated by IL‐22, in intestinal epithelial cells.Conclusions: C‐C chemokine receptor type 7 deficiency exacerbated NSAID‐induced enteropathy in association with an altered phenotype of CD103+ DCs that produces IL‐22BP. CCR7 contributes to protect the small intestine from NSAID‐induced mucosal injury.
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-266-266
Sa1169 - Deficiency of CCR7 is Responsible for the Deterioration of Non-Steroidal Anti-Inflammatory Drug-Induced Enteropathy in Mice
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-266-266
Sa1169 - Deficiency of CCR7 is Responsible for the Deterioration of Non-Steroidal Anti-Inflammatory Drug-Induced Enteropathy in Mice
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1779 - Oligosaccharide-Dependent Anti-Inflammatory Role of Galectin-1 in Inflammatory Bowel Disease
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1779 - Oligosaccharide-Dependent Anti-Inflammatory Role of Galectin-1 in Inflammatory Bowel Disease
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S558
Exosomes Derived From Colon Cancer Cells Promote Tumor Progression via the Activation of Fibroblasts in Tumor Microenvironment
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S558
Exosomes Derived From Colon Cancer Cells Promote Tumor Progression via the Activation of Fibroblasts in Tumor Microenvironment
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S945
Depressive Psychological Status is Associated with Disease Exacerbation in Remissive Crohn's Disease Patients: A Prospective Observational Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S945
Depressive Psychological Status is Associated with Disease Exacerbation in Remissive Crohn's Disease Patients: A Prospective Observational Study
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S571
Deficiency of CCR7 Deteriorates Non-Steroidal Anti-Inflammatory Drug-Induced Enteropathy in Mice
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S571
Deficiency of CCR7 Deteriorates Non-Steroidal Anti-Inflammatory Drug-Induced Enteropathy in Mice
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S571
Indigo Naturalis Ameliorates Murine Dextran Sodium Sulfate Induced-Colitis through the Activation of Aryl Hydrocarbon Receptor Independently of IL-10
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S571
Indigo Naturalis Ameliorates Murine Dextran Sodium Sulfate Induced-Colitis through the Activation of Aryl Hydrocarbon Receptor Independently of IL-10
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4)
Tu1300 Mucosal Drug Concentration and Clinical Characteristics of Crohn's Disease Patients Receiving Anti-TNF Therapy
- 1 April 2015
- Published by Elsevier in Gastroenterology
- Vol. 148 (4)
Tu1300 Mucosal Drug Concentration and Clinical Characteristics of Crohn's Disease Patients Receiving Anti-TNF Therapy